Peptide Lab HQ Research Guide
CJC-1295 with DAC
A research-focused compound profile covering CJC-1295 with DAC identity, long-acting GHRH analog research, drug affinity complex activity, GH / IGF-1 axis research, concentration reference, reconstitution reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | CJC-1295 with DAC |
|---|---|
| Common Synonyms | CJC-1295 DAC, CJC-1295, DAC-GRF, long-acting GHRH analog |
| Compound Type | Modified growth hormone-releasing hormone analog / long-acting peptide research compound |
| CAS Number | Commonly listed as 446262-90-4 or 863288-34-0 depending on reference and salt/form; verify against supplier COA |
| PubChem CID | 91971820 |
| Amino Acid Length | 30 amino acids with maleimidopropionyl-Lys DAC modification |
| Amino Acid Sequence | H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Maleimidopropionyl)-NH₂ |
| Short Sequence | Y-D-Ala-DAIFTQSYRKVAQLSARKLLQDILSRK(DAC)-NH₂ |
| Structural Feature | Modified GHRH analog with Drug Affinity Complex designed for albumin-binding and extended duration of activity |
| Molecular Formula | C₁₆₅H₂₆₉N₄₇O₄₆; verify against supplier COA |
| Molecular Weight | Approximately 3647.2 g/mol; verify against supplier COA |
| Research Category | GHRH receptor signaling, GH-axis research, IGF-1 response, pituitary signaling, endocrine-marker research, and long-acting peptide pharmacokinetic research |
| Research Context | Commonly discussed in controlled research involving sustained growth hormone release, IGF-1 response, GHRH receptor pathway activity, albumin-binding peptide design, and endocrine-response documentation. |
| Appearance | White to off-white lyophilized powder, depending on supplier documentation |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
CJC-1295 with DAC is commonly discussed in controlled research models involving GHRH receptor signaling, pituitary GH release, IGF-1 response, long-acting endocrine pathway activity, albumin-binding peptide design, and GH-axis biomarker documentation.
GHRH Receptor Research
CJC-1295 with DAC is studied as a modified GHRH analog designed to activate growth hormone-releasing hormone receptor pathways.
GH / IGF-1 Axis Models
Used in research involving growth hormone release, IGF-1 response, endocrine-marker tracking, and pituitary signaling documentation.
Long-Acting Peptide Research
The DAC modification is commonly discussed for its albumin-binding design and extended pharmacokinetic profile compared with shorter-acting GHRH fragments.
Endocrine Biomarker Research
Research contexts include GH pulse behavior, IGF-1 elevation, feedback response, and downstream endocrine-marker observations.
Combination Research Context
CJC-1295 with DAC is often discussed separately from secretagogues such as Ipamorelin because GHRH analogs and ghrelin-receptor agonists act through different signaling pathways.
Pharmacokinetic Research
CJC-1295 with DAC is commonly referenced in studies evaluating extended half-life, sustained exposure, and repeated-dose endocrine response.
Research Scope
These applications are provided for educational and research-reference purposes only. Research outcomes may vary based on peptide form, purity, concentration, receptor expression, model type, study timing, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Select Reference Vial
Select a vial size to update the concentration, U-100 unit references, and frequency table below.
Quick Reference Summary
| Reference Vial | 2 mg CJC-1295 with DAC |
|---|---|
| Primary Solution Volume | 2.0 mL bacteriostatic water |
| Primary Concentration | 1 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 1 mg/mL, 1 unit equals 0.01 mg / 10 mcg CJC-1295 with DAC. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear to slightly hazy depending on concentration and supplier format. Do not shake!
- Verify complete dissolution before recording the final preparation details.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | CJC-1295 with DAC, long-acting GHRH analog | CJC-1295 with DAC is commonly discussed as a growth hormone-releasing hormone analog designed for extended GH / IGF-1 axis research contexts. |
| DAC / Albumin-Binding Distinction | Drug Affinity Complex albumin-binding research context | This reference is for the DAC-containing format. It should not be treated the same as CJC-1295 w/o DAC / Modified GRF (1-29), which is commonly discussed as a shorter-acting non-DAC reference format. |
| GHRH Receptor Research | Growth hormone-releasing hormone receptor pathway context | Commonly discussed in GHRH receptor signaling, anterior pituitary response, GH-marker tracking, IGF-1 marker tracking, and endocrine-axis research contexts. |
| GH / IGF-1 Axis Research | Model-dependent endocrine-marker tracking | CJC-1295 with DAC research discussions commonly include sustained GH-marker response, IGF-1 marker response, somatotroph signaling, pituitary-axis response, and endocrine feedback documentation. |
| Long-Acting Peptide Design Context | Extended half-life and bioavailability research | Published CJC-1295 research discusses hGRF(1-29)-albumin bioconjugate design and extended plasma half-life as part of the long-acting GHRH analog research model. |
| Endocrine / Body-Composition Marker Research | Clinical-study context only | CJC-1295 with DAC has been discussed in clinical-study contexts involving GH, IGF-1, body-composition markers, growth models, and endocrine-marker observations. These contexts are not research-chemical dosing standards. |
| Public Protocol-Style Reference | Microgram-to-milligram reference examples | Public protocol-style references commonly describe CJC-1295 with DAC in microgram-to-milligram examples depending on the research model and preparation format. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, clinical-study references, preclinical references, public protocol-style references, wellness protocols, or public dosing pages should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 2 mg | 2.0 mL | 1 mg/mL |
| 5 mg | 2.0 mL | 2.5 mg/mL |
| 10 mg | 2.0 mL | 5 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 1 mg/mL | U-100 Unit Reference | Approx. References per 2 mg Vial |
|---|---|---|---|
| 25 mcg | 0.025 mL | 2.5 units | 80 |
| 50 mcg | 0.05 mL | 5 units | 40 |
| 0.1 mg / 100 mcg | 0.10 mL | 10 units | 20 |
| 0.25 mg / 250 mcg | 0.25 mL | 25 units | 8 |
| 0.5 mg / 500 mcg | 0.50 mL | 50 units | 4 |
| 1 mg / 1000 mcg | 1.00 mL | 100 units | 2 |
| 2 mg / 2000 mcg | 2.00 mL | 200 units | 1 |
| 5 mg / 5000 mcg | 5.00 mL | 500 units | 0.4 |
| 10 mg / 10000 mcg | 10.00 mL | 1000 units | 0.2 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Lower Microgram Reference | Calculation reference only | 25 mcg reference amount | 2.5 units / 0.025 mL |
| Standard Microgram Reference | Calculation reference only | 50 mcg reference amount | 5 units / 0.05 mL |
| Low Milligram Conversion Example | Public protocol-style reference, not a clinical dosing standard | 0.1 mg reference amount | 10 units / 0.10 mL |
| Mid-Range Conversion Example | Public protocol-style reference, not a clinical dosing standard | 250 mcg reference amount | 25 units / 0.25 mL |
| Upper Conversion Example | Calculation reference only | 0.5 mg reference amount | 50 units / 0.50 mL |
| High Conversion Example | Calculation reference only | 1 mg reference amount | 100 units / 1.00 mL |
| 2 mg Preparation Reference | Preparation-level calculation reference | 2 mg reference amount | 200 units / 2.00 mL |
| 5 mg Preparation Reference | Preparation-level calculation reference | 5 mg reference amount | 500 units / 5.00 mL |
| 10 mg Preparation Reference | Preparation-level calculation reference | 10 mg reference amount | 1000 units / 10.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Receptor Observation Window | 24–72 hours | May be used for GHRH receptor signaling, somatotroph-response markers, GH-marker context, intracellular signaling, or peptide-response documentation depending on the model. |
| Acute Endocrine Observation Window | Single session to several days | Used for short-term GH-marker comparison, pituitary-axis response, IGF-1 marker observation, or early pathway tracking depending on the research design. |
| Short Research Window | 1–2 weeks | May be used for early controlled observation involving GH-axis markers, IGF-1 marker tracking, endocrine-axis response, or peptide-stability comparison. |
| Standard Protocol-Style Window | 2–4 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Endocrine Observation Window | 4–12 weeks | Used when longer documentation is needed for endocrine-marker trends, GH / IGF-1 marker tracking, long-acting GHRH analog context, or follow-up marker documentation. |
| Follow-Up / Washout | 2–8 weeks | Used to document post-study observations, marker return, delayed response patterns, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. CJC-1295 with DAC is commonly discussed in long-acting GHRH analog, Drug Affinity Complex, albumin-binding peptide, GHRH receptor, anterior pituitary, GH-axis, IGF-1 marker, somatotroph-response, endocrine-axis, and peptide half-life research contexts. The selector above updates calculations for 2 mg, 5 mg, and 10 mg vial references, each reconstituted with 2.0 mL bacteriostatic water. This page is for the DAC-containing reference format and should not be treated as the same preparation as CJC-1295 w/o DAC / Modified GRF (1-29). Published study references, clinical-study contexts, preclinical research references, public protocol-style references, and wellness protocols are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
CJC-1295 with DAC is commonly discussed in research involving GHRH receptor signaling, sustained GH release, IGF-1 response, pituitary endocrine activity, albumin-binding peptide design, and long-acting pharmacokinetic pathway models.
Study Limitations
CJC-1295 research includes limited healthy-adult clinical studies, pharmacokinetic research, and endocrine-marker tracking. Findings should be interpreted according to study design, dose, peptide form, assay method, receptor response, and baseline endocrine status.
Safety Considerations
Research discussion should account for GH / IGF-1 pathway activity, glucose-related markers, edema or water-retention observations, cardiovascular response, increased heart rate, systemic vasodilatory reaction, peptide purity, sterility documentation, storage conditions, and qualified laboratory handling procedures.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.